Chronic Idiopathic Constipation (CIC) Drugs Market 2017 to 2025 – Industry, Share, Size, Trends and Forecast By Acute Market Reports

PR Comments Off on Chronic Idiopathic Constipation (CIC) Drugs Market 2017 to 2025 – Industry, Share, Size, Trends and Forecast By Acute Market Reports

Chronic Idiopathic Constipation (CIC) Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2017-2025, the chronic idiopathic constipation drugs market was valued at USD 1889.85 Mn in 2017, and is expected to reach USD 2857.45 Mn by 2025, expanding at a CAGR of 6.4% from 2017 to 2025.

Browse Full Report Here: http://www.acutemarketreports.com/report/chronic-idiopathic-constipation-cic-drugs-market

Market Insights

Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation – CIC are the major factors driving the CIC drugs market worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global market during forecast period.

In terms of geographical distribution, North America captures over 40% share of the global market revenue. US is the largest national market for CIC drugs due to greater prevalence of lifestyle respective diseases, higher incidence of constipation, higher healthcare spending and rather greater adoption of pharmaceuticals for treating ailments. As per the National Institutes of Health (NIH) CIC affects approximately 63 Mn individuals in the US. On the other hand, growing awareness in the rapidly developing Asian countries such as China and India will create significant growth opportunities in the Asia Pacific market.

Browse the complete report at: http://www.acutemarketreports.com/report/chronic-idiopathic-constipation-cic-drugs-market

In terms of market segmentation by drug type, Lubiprostone drugs segment currently dominates the market. However, the segment due to its relatively lower efficacy, patent loss and growing competition from Linaclotide will lose its dominance in the upcoming future. The Linaclotide drugs market for CIC treatment is anticipated to grow at a CAGR of 7.7% during 2017 – 2025.
Analyzing the symptoms, constipation is not considered as a disease but a condition, side effect or syndrome. This factor greatly contributes to the lesser visits from patients to address the issue. Thus over 65% of the CIC drugs market is captured by OTC drugs segment. The OTC market is expected to continue to dominate the market at a CAGR of 6.6% during 2017 – 2025.

Table of Content:

Download Free Request Sample: http://www.acutemarketreports.com/request-free-sample/103777

Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Global CIC Drugs Market Analysis
3.1 CIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Attractive Investment Proposition, 2015
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Adverse health effects from modern dietary habits
3.4.1.2 Cancer or other systematic disease
3.4.1.3 Increasing geriatric population
3.4.1.4 Better and effective drugs in pipeline
3.4.1.5 Increasing constipation problems as a side-effect frequently prescribed medicines
3.4.2 Restraints
3.4.2.1 Surgical treatments
3.4.2.2 Unawareness and Ignorance among people
3.4.2.3 Side-effects of the chronic idiopathic constipation drugs
3.4.3 Opportunities
3.4.3.1 Emerging APAC market
3.4.3.2 High unmet needs
3.5 Attractive Investment Proposition, 2017
3.6 Market Positioning of Key CIC Drugs Manufacturers

Chapter 7 Company Profiles
7.1 Actavis
7.1.1 Overview
7.1.2 Actavis Product Portfolio
7.1.3 Strategic Moves
7.1.4 SCOT Analysis
7.2 Chugai Pharmaceutical
7.2.1 Overview
7.2.2 Chugai Pharmaceuticals Products Portfolio
7.2.3 Strategic Moves
7.2.4 SCOT Analysis
7.3 Ferring International Center S.A.
7.3.1 Overview
7.3.2 Ferring Holdings Products Portfolio
7.3.3 SCOT Analysis
7.4 Synergy Pharmaceuticals
7.4.1 Overview
7.4.2 Synergy Pharmaceuticals Products Portfolio
7.4.3 SCOT Analysis
7.5 Pfizer
7.5.1 Overview
7.5.2 Pfizer Product Portfolio
7.5.3 SCOT Analysis
7.6 GlaxoSmithKline
7.6.1 Overview
7.6.2 GlaxoSmithKline Product Portfolio
7.6.3 SCOT Analysis
7.7 Roche Holding AG
7.7.1 Overview
7.7.2 Roche AG Product Portfolio
7.7.3 Strategic Moves
7.7.4 SCOT Analysis
7.8 Sanofi
7.8.1 Overview
7.8.2 Sanofi Products Portfolio
7.8.3 SCOT Analysis
7.9 Bayer AG
7.9.1 Overview
7.9.2 Bayer AG Products Portfolio
7.9.3 SCOT Analysis
7.10 Salix Pharmaceuticals Ltd
7.10.1 Overview
7.10.2 Salix Pharmaceuticals Product Portfolio
7.10.3 SCOT Analysis
7.11 Sucampo Pharmaceuticals Inc
7.11.1 Overview
7.11.2 Sucampo Pharmaceuticals Product Portfolio
7.11.3 SCOT Analysis
7.12 Ironwood Pharmaceuticals inc
7.12.1 Overview
7.12.2 Ironwood Pharmaceuticals Product Portfolio
7.12.3 SCOT Analysis
7.13 Progenics pharmaceuticals inc
7.13.1 Overview
7.13.2 Progenics Pharmaceuticals product portfolio
7.13.3 SCOT Analysis

Latest Reports:

http://www.acutemarketreports.com/report/unleaded-petrol-market-report

http://www.acutemarketreports.com/report/oral-syringes-market-report

About – Acute Market Reports:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.

Contact Us:

Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com

Author

Back to Top